Pathway ID |
Pathway Name |
p-Value |
Adjusted p-Value |
Enriched Genes |
hsa05212 |
Pancreatic cancer_Homo sapiens_hsa05212 |
5.558E-06 |
4.946E-04 |
STAT3; TP53; NFKB1 |
hsa04210 |
Apoptosis_Homo sapiens_hsa04210 |
5.316E-05 |
1.072E-03 |
LMNA; TP53; NFKB1 |
hsa05160 |
Hepatitis C_Homo sapiens_hsa05160 |
4.562E-05 |
1.072E-03 |
STAT3; TP53; NFKB1 |
hsa05162 |
Measles_Homo sapiens_hsa05162 |
4.876E-05 |
1.072E-03 |
STAT3; TP53; NFKB1 |
hsa05161 |
Hepatitis B_Homo sapiens_hsa05161 |
6.024E-05 |
1.072E-03 |
STAT3; TP53; NFKB1 |
hsa05169 |
Epstein-Barr virus infection_Homo sapiens_hsa05169 |
1.578E-04 |
1.833E-03 |
STAT3; TP53; NFKB1 |
hsa05203 |
Viral carcinogenesis_Homo sapiens_hsa05203 |
1.648E-04 |
1.833E-03 |
STAT3; TP53; NFKB1 |
hsa04010 |
MAPK signaling pathway_Homo sapiens_hsa04010 |
3.133E-04 |
3.099E-03 |
MAPT; TP53; NFKB1 |
hsa05221 |
Acute myeloid leukemia_Homo sapiens_hsa05221 |
4.317E-04 |
3.704E-03 |
STAT3; NFKB1 |
hsa00591 |
Linoleic acid metabolism_Homo sapiens_hsa00591 |
1.108E-04 |
1.643E-03 |
CYP3A4; CYP2C19 |
hsa05206 |
MicroRNAs in cancer_Homo sapiens_hsa05206 |
4.897E-04 |
3.704E-03 |
STAT3; TP53; NFKB1 |
hsa05321 |
Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 |
5.613E-04 |
3.704E-03 |
STAT3; NFKB1 |
hsa00830 |
Retinol metabolism_Homo sapiens_hsa00830 |
5.613E-04 |
3.704E-03 |
ALDH1A1; CYP3A4 |
hsa04917 |
Prolactin signaling pathway_Homo sapiens_hsa04917 |
6.883E-04 |
3.704E-03 |
STAT3; NFKB1 |
hsa05200 |
Pathways in cancer_Homo sapiens_hsa05200 |
1.138E-03 |
4.731E-03 |
STAT3; TP53; NFKB1 |
hsa00982 |
Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 |
6.323E-04 |
3.704E-03 |
CYP3A4; CYP2C19 |
hsa05220 |
Chronic myeloid leukemia_Homo sapiens_hsa05220 |
7.075E-04 |
3.704E-03 |
TP53; NFKB1 |
hsa04920 |
Adipocytokine signaling pathway_Homo sapiens_hsa04920 |
6.507E-04 |
3.704E-03 |
STAT3; NFKB1 |
hsa05215 |
Prostate cancer_Homo sapiens_hsa05215 |
1.049E-03 |
4.669E-03 |
TP53; NFKB1 |
hsa04933 |
AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 |
1.348E-03 |
5.197E-03 |
STAT3; NFKB1 |
hsa05222 |
Small cell lung cancer_Homo sapiens_hsa05222 |
9.802E-04 |
4.591E-03 |
TP53; NFKB1 |
hsa04211 |
Longevity regulating pathway - mammal_Homo sapiens_hsa04211 |
1.169E-03 |
4.731E-03 |
TP53; NFKB1 |
hsa05204 |
Chemical carcinogenesis_Homo sapiens_hsa05204 |
8.917E-04 |
4.409E-03 |
CYP3A4; CYP2C19 |
hsa04066 |
HIF-1 signaling pathway_Homo sapiens_hsa04066 |
1.402E-03 |
5.197E-03 |
STAT3; NFKB1 |
hsa04931 |
Insulin resistance_Homo sapiens_hsa04931 |
1.568E-03 |
5.581E-03 |
STAT3; NFKB1 |
hsa05145 |
Toxoplasmosis_Homo sapiens_hsa05145 |
1.833E-03 |
6.024E-03 |
STAT3; NFKB1 |
hsa04722 |
Neurotrophin signaling pathway_Homo sapiens_hsa04722 |
1.895E-03 |
6.024E-03 |
TP53; NFKB1 |
hsa04630 |
Jak-STAT signaling pathway_Homo sapiens_hsa04630 |
3.255E-03 |
9.989E-03 |
THPO; STAT3 |
hsa04071 |
Sphingolipid signaling pathway_Homo sapiens_hsa04071 |
1.895E-03 |
6.024E-03 |
TP53; NFKB1 |
hsa05205 |
Proteoglycans in cancer_Homo sapiens_hsa05205 |
5.309E-03 |
1.432E-02 |
STAT3; TP53 |
hsa04062 |
Chemokine signaling pathway_Homo sapiens_hsa04062 |
4.524E-03 |
1.258E-02 |
STAT3; NFKB1 |
hsa05202 |
Transcriptional misregulation in cancer_Homo sapiens_hsa05202 |
4.200E-03 |
1.246E-02 |
TP53; NFKB1 |
hsa05168 |
Herpes simplex infection_Homo sapiens_hsa05168 |
4.431E-03 |
1.258E-02 |
TP53; NFKB1 |
hsa05166 |
HTLV-I infection_Homo sapiens_hsa05166 |
8.443E-03 |
2.210E-02 |
TP53; NFKB1 |
hsa04151 |
PI3K-Akt signaling pathway_Homo sapiens_hsa04151 |
1.440E-02 |
3.560E-02 |
TP53; NFKB1 |
hsa05216 |
Thyroid cancer_Homo sapiens_hsa05216 |
1.584E-02 |
3.810E-02 |
TP53 |
hsa04614 |
Renin-angiotensin system_Homo sapiens_hsa04614 |
1.258E-02 |
3.199E-02 |
CMA1 |